BIO - Why Is Clinical Diagnostic-Focused Bio-Rad Stock Trading Lower Today? | Benzinga
Bio-Rad Laboratories Inc (NYSE: BIO) shares are trading lower after the company lowered its annual revenue growth forecast, citing the uncertain pace of the biopharma sector's recovery and the ongoing macro challenges.
The company reported Q3 sales of $632.1 million, missing the consensus of $689.57 million. Adjusted EPS reached $2.33, down from 2.64 a year ago and missing the consensus ...